MedTrace Logo

The Success of Opening Concurrent CTO leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease

NCT03372785 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2020-09-01

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect of percutaneous coronary intervention (PCI) on cardiac function in multi-vessel disease patients with concurrent chronic total occlusion (CTO) lesion.

Conditions

  • Chronic Total Occlusion of Coronary Artery
  • Percutaneous Coronary Intervention
  • Coronary Artery Disease
  • Viable Myocardium

Interventions

DRUG

aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor

Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.

DEVICE

coronary wires. stents or coronary balloons

all species of drug-eluting stent ((such as Xience, Endeavor, Resolute) implantation or balloon expansion (POBA)

Sponsors & Collaborators

  • The First Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • Beijing Friendship Hospital

    collaborator OTHER

  • Beijing Anzhen Hospital

    lead OTHER

Principal Investigators

  • Xiantao Song, MD · Beijing Anzhen Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-10
Primary Completion
2021-12-31
Completion
2022-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03372785 on ClinicalTrials.gov